Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity
- PMID:16344479
- PMCID: PMC1311737
- DOI: 10.1073/pnas.0508254102
Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity
Abstract
Apolipoprotein (apo) E4, a 299-aa protein and a major risk factor for Alzheimer's disease, can be cleaved to generate C-terminal-truncated fragments that cause neurotoxicity in vitro and neurodegeneration and behavioral deficits in transgenic mice. To investigate this neurotoxicity, we expressed apoE4 with C- or N-terminal truncations or mutations in transfected Neuro-2a cells. ApoE4 (1-272) was neurotoxic, but full-length apoE4(1-299) and apoE4(1-240) were not, suggesting that the lipid-binding region (amino acids 241-272) mediates the neurotoxicity and that amino acids 273-299 are protective. A quadruple mutation in the lipid-binding region (I250A, F257A, W264R, and V269A) abolished the neurotoxicity of apoE4(1-272), and single mutations in the region of amino acids 273-299 (L279Q, K282A, or Q284A) made full-length apoE4 neurotoxic. Immunofluorescence staining showed that apoE4(1-272) formed filamentous inclusions containing phosphorylated tau in some cells and interacted with mitochondria in others, leading to mitochondrial dysfunction as determined by MitoTracker staining and flow cytometry. ApoE4(241-272) did not cause mitochondrial dysfunction or neurotoxicity, suggesting that the lipid-binding region alone is insufficient for neurotoxicity. Truncation of N-terminal sequences (amino acids 1-170) containing the receptor-binding region (amino acids 135-150) and triple mutations within that region (R142A, K146A, and R147A) abolished the mitochondrial interaction and neurotoxicity of apoE4(1-272). Further analysis showed that the receptor-binding region is required for escape from the secretory pathway and that the lipid-binding region mediates mitochondrial interaction. Thus, the lipid- and receptor-binding regions in apoE4 fragments act together to cause mitochondrial dysfunction and neurotoxicity, which may be important in Alzheimer's disease pathogenesis.
Figures





Similar articles
- Effect of carboxyl-terminal truncation on structure and lipid interaction of human apolipoprotein E4.Tanaka M, Vedhachalam C, Sakamoto T, Dhanasekaran P, Phillips MC, Lund-Katz S, Saito H.Tanaka M, et al.Biochemistry. 2006 Apr 4;45(13):4240-7. doi: 10.1021/bi060023b.Biochemistry. 2006.PMID:16566598
- Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease.Chen HK, Ji ZS, Dodson SE, Miranda RD, Rosenblum CI, Reynolds IJ, Freedman SB, Weisgraber KH, Huang Y, Mahley RW.Chen HK, et al.J Biol Chem. 2011 Feb 18;286(7):5215-21. doi: 10.1074/jbc.M110.151084. Epub 2010 Nov 30.J Biol Chem. 2011.PMID:21118811Free PMC article.
- Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease.Huang Y.Huang Y.Trends Mol Med. 2010 Jun;16(6):287-94. doi: 10.1016/j.molmed.2010.04.004. Epub 2010 May 27.Trends Mol Med. 2010.PMID:20537952Review.
- Amyloid-peptide β 42 Enhances the Oligomerization and Neurotoxicity of apoE4: The C-terminal Residues Leu279, Lys282 and Gln284 Modulate the Structural and Functional Properties of apoE4.Dafnis I, Argyri L, Chroni A.Dafnis I, et al.Neuroscience. 2018 Dec 1;394:144-155. doi: 10.1016/j.neuroscience.2018.10.026. Epub 2018 Oct 24.Neuroscience. 2018.PMID:30367942
- Molecular and cellular mechanisms of apolipoprotein E4 neurotoxicity and potential therapeutic strategies.Huang Y.Huang Y.Curr Opin Drug Discov Devel. 2006 Sep;9(5):627-41.Curr Opin Drug Discov Devel. 2006.PMID:17002223Review.
Cited by
- Functional diversity of apolipoprotein E: from subcellular localization to mitochondrial function.Rueter J, Rimbach G, Huebbe P.Rueter J, et al.Cell Mol Life Sci. 2022 Aug 26;79(9):499. doi: 10.1007/s00018-022-04516-7.Cell Mol Life Sci. 2022.PMID:36018414Free PMC article.Review.
- New insights in lipid metabolism: potential therapeutic targets for the treatment of Alzheimer's disease.Cao Y, Zhao LW, Chen ZX, Li SH.Cao Y, et al.Front Neurosci. 2024 Sep 11;18:1430465. doi: 10.3389/fnins.2024.1430465. eCollection 2024.Front Neurosci. 2024.PMID:39323915Free PMC article.Review.
- Human apolipoprotein E4 worsens acute axonal pathology but not amyloid-β immunoreactivity after traumatic brain injury in 3xTG-AD mice.Bennett RE, Esparza TJ, Lewis HA, Kim E, Mac Donald CL, Sullivan PM, Brody DL.Bennett RE, et al.J Neuropathol Exp Neurol. 2013 May;72(5):396-403. doi: 10.1097/NEN.0b013e31828e24ab.J Neuropathol Exp Neurol. 2013.PMID:23584199Free PMC article.
- Mass spectrometry quantification revealed accumulation of C-terminal fragment of apolipoprotein E in the Alzheimer's frontal cortex.Wang M, Turko IV.Wang M, et al.PLoS One. 2013 Apr 11;8(4):e61498. doi: 10.1371/journal.pone.0061498. Print 2013.PLoS One. 2013.PMID:23593485Free PMC article.
- Comparative profiling of the synaptic proteome from Alzheimer's disease patients with focus on the APOE genotype.Hesse R, Hurtado ML, Jackson RJ, Eaton SL, Herrmann AG, Colom-Cadena M, Tzioras M, King D, Rose J, Tulloch J, McKenzie CA, Smith C, Henstridge CM, Lamont D, Wishart TM, Spires-Jones TL.Hesse R, et al.Acta Neuropathol Commun. 2019 Dec 20;7(1):214. doi: 10.1186/s40478-019-0847-7.Acta Neuropathol Commun. 2019.PMID:31862015Free PMC article.
References
- Mahley, R. W. (1988) Science 240, 622-630. - PubMed
- Mahley, R. W. & Huang, Y. (1999) Curr. Opin. Lipidol. 10, 207-217. - PubMed
- Huang, Y. & Mahley, R. W. (1999) in Plasma Lipids and Their Role in Disease, eds. Barter, P. J. & Rye, K.-A. (Harwood, Amsterdam), pp. 257-284.
- Mahley, R. W. & Rall, S. C., Jr., (2000) Annu. Rev. Genomics Hum. Genet. 1, 507-537. - PubMed
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources